Company has announced the launch of Absorica capsules in the strengths of 25 mg and 35 mg
New Delhi, October 07, 2014 – Drug firm Ranbaxy Laboratories today launched Absorica capsules used for treatment of severe acne in the American market.
Ranbaxy Laboratories Inc, a subsidiary of the company has announced the launch of Absorica capsules in the strengths of 25 mg and 35 mg in the US market.
“The product is licensed to Ranbaxy from Cipher Pharmaceuticals Inc,” Ranbaxy Laboratories said in a statement.
Ranbaxy North America Brand Division Vice President Ashish Anvekar said: “Since isotretinoin dosing is weight- based, we are most pleased to make available these valuable, additional dosing options exclusively for Absorica.”
This will give prescriber’s the enhanced flexibility, to tailor the isotretinoin therapy depending on the patient’s weight, and benefit the group of patients who are in that weight range, irrespective of their dietary intake, he added.
“The capsules are indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older,” the company said.
The medicine must not be used by female patients who are or may become pregnant. Absorica is only available through a restricted distribution program called iPLEDGE, it added.
In April, Sun Pharmaceutical Industries had announced to acquire Ranbaxy Laboratories in a $4-billion deal. PTI
